The expression of plasma lncRNA CEBPA-AS1 and miR-139-5p in patients with acute cerebral infarction and their correlation with cognitive dysfunction

doi:10.11958/20241422

Abstract

Abstract:

Objective To detect levels of plasma long non coding RNA (lncRNA) CCAAT enhancer binding protein alpha antisense 1 (CEBPA-AS1) and microRNA-139-5p (miR-139-5p) in patients with acute cerebral infarction (ACI), and to explore their relationship with cognitive dysfunction in ACI patients.Methods A total of 132 ACI patients treated in our hospital were included for the study. The Montreal Cognitive Assessment Scale (MoCA) was used to evaluate the cognitive function of ACI patients, and they were diveded into the cognitive dysfunction group (n=63) and the normal cognitive function group (n=69). The general data of the two groups were compared. The qRT-PCR method was applied to measure plasma levels of lncRNA CEBPA-AS1 and miR-139-5p in ACI patients. Pearson method was applied to analyze the correlation between plasma lncRNA CEBPA-AS1 and miR-139-5p in ACI patients. Multivariate Logistic regression was applied to analyze factors influencing cognitive dysfunction in ACI patients. Receiver operating characteristic (ROC) curve was applied to evaluate the diagnostic value of plasma lncRNA CEBPA-AS1 and miR-139-5p for cognitive dysfunction in ACI patients.Results Compared with the normal cognitive function group, the plasma lncRNA CEBPA-AS1 was higher and the miR-139-5p was lower in the cognitive dysfunction group (P<0.05). Correlation analysis showed that there was a negative correlation between lncRNA CEBPA-AS1 and miR-139-5p (r=-0.462, P<0.01). Multivariate analysis showed that high school education or below, decreased plasma miR-139-5p, and increased lncRNA CEBPA-AS1 were risk factors for cognitive dysfunction in ACI patients (P<0.05). The area under the curve (AUC) of lncRNA CEBPA-AS1 and miR-139-5p in the diagnosis of cognitive dysfunction in ACI patients was 0.865 and 0.798, respectively. The combined diagnostic efficacy of the two (AUC=0.912) was better than single index.Conclusion The plasma lncRNA CEBPA-AS1 is increased and the plasma miR-139-5p is decreased in patients with ACI combined with cognitive dysfunction, and both are influencing factors for cognitive dysfunction in ACI patients, and the combined diagnostic efficacy is high.

Key words: cognitive dysfunction, cerebral infarction, acute disease, long non coding RNA CEBPA-AS1, miR-139-5p

CLC Number:

R741

Figures/Tables 7

References 19

[1]	GBD 2019 STROKE COLLABORATORS. Global,regional,and national burden of stroke and its risk factors,1990-2019:a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Neurol,2021, 20(10):795-820. doi:10.1016/S1474-4422(21)00252-0.
[2]	WANG F, HUA S, ZHANG Y, et al. Association between small vessel disease markers,medial temporal lobe atrophy and cognitive impairment after stroke:a systematic review and meta-analysis[J]. J Stroke Cerebrovasc Dis, 2021, 30(1):105460. doi:10.1016/j.jstrokecerebrovasdis.2020.105460.
[3]	王新波, 罗冰清, 石玉宝, 等. 结直肠癌组织LncRNA LINC00342和miR-203a-3p表达及与预后的关系[J]. 天津医药, 2024, 52(9):971-976.
	WANG X B, LING B Q, SHI Y B, et al. Expression of LncRNA LINC00342 and miR-203a-3p in colorectal cancer tissues and their relationship with prognosis[J]. Tianjin Med J, 2024, 52(9):971-976. doi:10.11958/20231812.
[4]	TU X, ZHANG H, CHEN S, et al. LncRNA CEBPA-AS1 alleviates cerebral ischemia-reperfusion injury by sponging miR-340-5p regulating APPL1/LKB1/AMPK pathway[J]. FASEB J, 2022, 36(1):e22075. doi:10.1096/fj.202100826RR.
[5]	方韶韩, 朱晓雷, 张潇文, 等. MiR-139-5p的研究进展[J]. 中国胸心血管外科临床杂志, 2023, 30(1):149-153.
	FANG S H, ZHU X L, ZHANG X W, et al. Research progress of miR-139-5p[J]. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023, 30(1):149-153. doi:10.7507/1007-4848.202101103.
[6]	庄静, 陈全景. 新生儿缺氧缺血性脑损伤中微小RNA的研究进展[J]. 儿科药学杂志, 2021, 27(12):53-57.
	ZHUANG J, CHEN Q J. Progress of MicroRNA in neonatal hypoxic-ischemic brain damage[J]. Journal of Pediatric Pharmacy, 2021, 27(12):53-57. doi:10.13407/j.cnki.jpp.1672-108X.2021.12.016.
[7]	YAO Y, HU S, ZHANG C, et al. Ginsenoside Rd attenuates cerebral ischemia/reperfusion injury by exerting an anti-pyroptotic effect via the miR-139-5p/FoxO1/Keap1/Nrf2 axis[J]. Int Immunopharmacol, 2022,105:108582. doi:10.1016/j.intimp.2022.108582.
[8]	中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9):666-682.
	Chinese Society of Neurology,Cerebrovascular Disease Group of the Neurology Branch of the Chinese Medical Association. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018[J]. Chinese Journal of Neurology, 2018, 51(9):666-682. doi:10.3760/cma.j.issn.1006-7876.2018.09.004.
[9]	许莉, 李慧英. 脑梗死急性期患者糖化血红蛋白和纤维蛋白原水平与认知功能障碍的关系[J]. 中华老年心脑血管病杂志, 2018, 20(6):627-630.
	XU L, LI H Y. Relationship of HbAlc rate and serum fibrinogen level with cognitive impairment in acute ischemic stroke patients[J]. Chin J Geriatr Heart Brain Vessel Dis, 2018, 20(6):627-630. doi:10.3969/j.issn.1009-0126. 2018.06.018.
[10]	YANG J, DUAN J, LI M, et al. Aldehyde dehydrogenase isoform 1 predicts a poor prognosis of acute cerebral infarction[J]. Contrast Media Mol Imaging, 2022,2022:8199917. doi:10.1155/2022/8199917.
[11]	YAN H, CHEN H, LIU Y, et al. Assessment of cognitive impairment after acute cerebral infarction with T1 relaxation time measured by MP2RAGE sequence and cerebral hemodynamic by transcranial Doppler[J]. Front Neurol, 2022,13:1056423. doi:10.3389/fneur.2022.1056423.
[12]	CHEN Y, LI Z, CHEN X, et al. Long non-coding RNAs:from disease code to drug role[J]. Acta Pharm Sin B, 2021, 11(2):340-354. doi:10.1016/j.apsb.2020.10.001.
[13]	DI G, YANG X, CHENG F, et al. CEBPA-AS1 knockdown alleviates oxygen-glucose deprivation/reperfusion-induced neuron cell damage by the microRNA 24-3p/bok axis[J]. Mol Cell Biol, 2021, 41(8):e0006521. doi:10.1128/MCB.00065-21.
[14]	PENG J, YU Z T, XIAO R J, et al. LncRNA CEBPA-AS1 knockdown prevents neuronal apoptosis against oxygen glucose deprivation/reoxygenation by regulating the miR-455/GPER1 axis[J]. Metab Brain Dis, 2022, 37(3):677-688. doi:10.1007/s11011-021-00881-7.
[15]	JEBARI-BENSLAIMAN S, GALICIA-GARCÍA U, LARREA-SEBAL A, et al. Pathophysiology of atherosclerosis[J]. Int J Mol Sci, 2022, 23(6):3346. doi:10.3390/ijms23063346.
[16]	IMYANITOV E N, IYEVLEVA A G, LEVCHENKO E V. Molecular testing and targeted therapy for non-small cell lung cancer:current status and perspectives[J]. Crit Rev Oncol Hematol, 2021,157:103194. doi:10.1016/j.critrevonc.2020.103194.
[17]	FLEMMING J P, HILL B L, HAQUE M W, et al. miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas[J]. J Extracell Vesicles, 2020, 9(1):1790159. doi:10.1080/20013078.2020.1790159.
[18]	张丽蓉, 林艾, 杨丽. 缺氧缺血性脑病新生儿血清miR-139-5p,HDAC4和GFAP表达水平及其临床价值研究[J]. 现代检验医学杂志, 2024, 39(1):55-60.
	ZHANG L R, LIN A, YANG L. Study on the expression levels of serum miR-139-5p,HDAC4 and GFAP in neonates with hypoxic-ischemic encephalopathy and their clinical value[J]. J Mod Lab Med, 2024, 39(1):55-60. doi:10.3969/j.issn.1671-7414.2024.01.010.
[19]	史文倩, 赵美英, 黄捷, 等. MiR-139-5p靶向RIPK1/RIPK3/MLKL信号通路对慢性脑低灌注大鼠认知障碍的影响[J]. 天津医药, 2023, 51(11):1187-1193.
	SHI W Q, ZHAO M Y, HUANG J, et al. Effect of MiR-139-5p targeting RIPK1/RIPK3/MLKL signaling pathway on cognitive impairment in rats with chronic cerebral hypoperfusion[J]. Tianjin Med J, 2023, 51(11):1187-1193. doi:10.11958/20230110.

组别		n	年龄/岁			性别				受教育程度
组别		n	年龄/岁			男		女		大学及以上				高中及以下
认知功能正常组		69	60.90±8.72			36（52.17）		33（47.83）		45（65.22）				24（34.78）
认知功能障碍组		63	62.64±8.81			32（50.79）		31（49.21）		13（20.63）				50（79.37）
t或χ²			1.139			0.025					26.572^＊＊
组别	基础病史								饮酒			吸烟	MoCA评分/分
组别	高血压				糖尿病		冠心病		饮酒			吸烟	MoCA评分/分
认知功能正常组	37（53.62）				39（56.52）		45（65.22）		13（18.84）			32（46.38）	28.25±1.72
认知功能障碍组	36（57.14）				38（60.32）		43（68.25）		17（26.98）			27（42.86）	20.14±2.31
t或χ²	0.165			0.195			0.137		1.244			0.165	23.006^＊＊

组别		n	年龄/岁			性别				受教育程度
组别		n	年龄/岁			男		女		大学及以上				高中及以下
认知功能正常组		69	60.90±8.72			36（52.17）		33（47.83）		45（65.22）				24（34.78）
认知功能障碍组		63	62.64±8.81			32（50.79）		31（49.21）		13（20.63）				50（79.37）
t或χ²			1.139			0.025					26.572^＊＊
组别	基础病史								饮酒			吸烟	MoCA评分/分
组别	高血压				糖尿病		冠心病		饮酒			吸烟	MoCA评分/分
认知功能正常组	37（53.62）				39（56.52）		45（65.22）		13（18.84）			32（46.38）	28.25±1.72
认知功能障碍组	36（57.14）				38（60.32）		43（68.25）		17（26.98）			27（42.86）	20.14±2.31
t或χ²	0.165			0.195			0.137		1.244			0.165	23.006^＊＊

基因名称	引物序列（5′→3′）	产物大小/ bp
LncRNA CEBPA-AS1	上游：GCTTCGTTTTCGGTCCAGA	152
	下游：CCCTCCACAGGTGAATGCTAT	152
GAPDH	上游：GCTGCAGAGGTCCGAAGAA	136
	下游：GCTGCAGAAGGTCCGAAGAA	136
miR-139-5p	上游：CATCGCGCATGCTAGCTAGACC	58
	下游：ATACGGCAACGTACGCGACGCATA	58
U6	上游：GCTGGACTCTAGGGTGCAAG	141
	下游：GAGCATACCAGGTGGTAGTAG	141

基因名称	引物序列（5′→3′）	产物大小/ bp
LncRNA CEBPA-AS1	上游：GCTTCGTTTTCGGTCCAGA	152
	下游：CCCTCCACAGGTGAATGCTAT	152
GAPDH	上游：GCTGCAGAGGTCCGAAGAA	136
	下游：GCTGCAGAAGGTCCGAAGAA	136
miR-139-5p	上游：CATCGCGCATGCTAGCTAGACC	58
	下游：ATACGGCAACGTACGCGACGCATA	58
U6	上游：GCTGGACTCTAGGGTGCAAG	141
	下游：GAGCATACCAGGTGGTAGTAG	141

组别	n	LncRNA CEBPA-AS1	miR-139-5p
认知功能正常组	69	1.02±0.04	0.99±0.03
认知功能障碍组	63	1.26±0.28	0.82±0.16
t		7.044^＊＊	8.664^＊＊